

## **Brazil Blood Glucose Monitoring - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2018 - 2029**

Market Report | 2024-02-17 | 70 pages | Mordor Intelligence

### **AVAILABLE LICENSES:**

- Single User License \$4750.00
- Team License (1-7 Users) \$5250.00
- Site License \$6500.00
- Corporate License \$8750.00

### **Report description:**

The Brazil Blood Glucose Monitoring Market size is estimated at USD 629.61 million in 2024, and is expected to reach USD 916.57 million by 2029, growing at a CAGR of 7.80% during the forecast period (2024-2029).

One of the most significant risk factors for a severe course of COVID-19 is diabetes mellitus. This risk is believed to be influenced by several variables that are frequently present in diabetes mellitus, such as advanced age, a proinflammatory and hypercoagulable condition, hyperglycemia, and underlying comorbidities (hypertension, cardiovascular disease, chronic kidney disease, and obesity). Diabetes was quickly recognized as a risk factor for bad results during the COVID-19 pandemic. That's why managing or delaying diabetes became more important than ever before. Several studies have confirmed that chronic diseases like diabetes are associated with adverse outcomes in COVID-19 patients.

Diabetes is associated with many health complications. Comparing the population with and without diabetes, those with diabetes have a 300% increased risk of being hospitalized and, thus, incur more healthcare expenses compared to non-diabetic people. People with diabetes face a higher chance of experiencing serious complications from COVID-19. In general, people with diabetes are more likely to experience severe symptoms and complications when infected with a virus. Diabetes and high glucose levels are associated with increased complications, respiratory failure, and mortality in hospitalized patients with coronavirus.

Brazil has implemented a set of reforms over the past to improve the distribution of doctors, develop new forms of the service organization, introduce new financing models, and implement a range of quality improvement initiatives and policy frameworks to overcome risk factors such as obesity and emerging pandemic threats. The pandemic also highlighted opportunities for continuing and expanding innovations in the delivery of diabetes care, through virtual consultations between healthcare providers and people with diabetes, and the use of diabetes technology. Crisis management has created unprecedented interest in remote care

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

from both patients and providers and removed many long-standing regulatory barriers. Thus, the COVID-19 outbreak increased the blood glucose monitoring market's growth.

## Brazil Blood Glucose Monitoring Market Trends

### Rising diabetes prevalence

Brazil's diabetes population is expected to increase with a CAGR of about 2.9% over the forecast period.

According to IDF Diabetes Atlas 2021, 15.7 million adults, about 10.5%, were living with diabetes in Brazil - or one in ten adults. The cost of diabetes-related health expenditure in Brazil is the third highest in the world, at USD 42.9 billion. In addition, 18 million adults, around 11.9%, suffer from Impaired Glucose Tolerance which places them at high risk of developing type 2 diabetes. Diabetes is associated with many health complications. Comparing the population with and without diabetes, those with diabetes include an increased risk of being hospitalized and, thus, incur more healthcare expenses than non-diabetic people. Additional data on glycaemic control in Brazil show that only 25% met the therapeutic goal of glycated hemoglobin (HbA1c) < 7% before the pandemic, as recommended by the Brazilian Diabetes Society (SBD).

The high prevalence of diabetes is associated with a significant economic burden. The costs of diabetes are increased in patients with co-morbidities such as hypertension and hyperlipidemia and in patients who develop complications. Costs increase with an increasing number of complications. The Ministry of Health established a list of medications and supplies the Brazilian Health System provides to patients suffering from diabetes. However, their supply usually needs to be increased or recommended for optimal patient management across cities. In Brazil, the public health system Sistema Unico de Saude (SUS) progressively increased the assistance available for individuals with diabetes.

Therefore, owing to the increasing diabetes prevalence and factors above, the studied market is anticipated to grow over the analysis period.

The continuous glucose monitoring segment is expected to witness the highest growth rate over the forecast period

The Continuous Glucose Monitoring Segment is expected to grow at a CAGR of about 11.9% over the forecast period.

To use a CGM, a small sensor is inserted into the abdomen or arm with a tiny plastic tube known as a cannula penetrating the top layer of skin. An adhesive patch holds the sensor in place, allowing it to take glucose readings in interstitial fluid throughout the day and night. Generally, the sensors must be replaced every 7 to 14 days. A small, reusable transmitter connected to the sensor allows the system to send real-time readings wirelessly to a monitor device that displays blood glucose data. Some systems come with a dedicated monitor, and some display the information via a smartphone app.

CGM sensors proved to be effective for patients with frequent hypoglycemic events, sensor-augmented pumps, and gestational diabetes, treated with either continuous subcutaneous insulin infusion or a multiple daily injections insulin regimen. Researchers are trying to find and develop alternatives to electrochemical-based glucose sensors and create more affordable, minimally invasive, and user-friendly CGM sensors. Optical measurement is a promising platform for glucose sensing. Some technologies with high potential in continuous glucose sensing are reported, including spectroscopy, fluorescence, holographic technology, etc. Eversense, a CGM sensor based on fluorescence sensing developed by Senseonics Company, presents a much longer lifespan than electrochemical sensors.

CGM devices must be used alongside insulin pumps. As the trends show a higher number of diabetic patients using insulin pumps for diabetes management, it can be predicted that the number of units of CGM devices sold will also follow. Type-1 patients

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

require continuous monitoring to closely monitor their glucose levels, which will likely generate demand in the coming years. Due to the adaptability of new technology and the high prevalence of diabetes, the market studied is expected to grow.

## Brazil Blood Glucose Monitoring Industry Overview

The Brazil Blood Glucose Monitoring Market is moderately fragmented, with few significant and generic players. Constant innovations are driven by manufacturers such as Abbott and Medtronic while adhering to organic growth strategies. It is evident from the R&D spending of these companies.

Additional Benefits:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

### **Table of Contents:**

#### 1 INTRODUCTION

- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study

#### 2 RESEARCH METHODOLOGY

#### 3 EXECUTIVE SUMMARY

#### 4 MARKET DYNAMICS

- 4.1 Market Overview
- 4.2 Market Drivers
- 4.3 Market Restraints
- 4.4 Porter's Five Forces Analysis
  - 4.4.1 Bargaining Power of Suppliers
  - 4.4.2 Bargaining Power of Consumers
  - 4.4.3 Threat of New Entrants
  - 4.4.4 Threat of Substitute Products and Services
  - 4.4.5 Intensity of Competitive Rivalry

#### 5 MARKET SEGMENTATION

- 5.1 Type
  - 5.1.1 Self-monitoring blood glucose devices
    - 5.1.1.1 Glucometer Devices
    - 5.1.1.2 Test Strips
    - 5.1.1.3 Lancets
  - 5.1.2 Continuous blood glucose monitoring devices
    - 5.1.2.1 Sensors
    - 5.1.2.2 Durables (Receivers and Transmitters)

#### 6 MARKET INDICATORS

- 6.1 Type-1 Diabetes population
- 6.2 Type-2 Diabetes population

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

## 7 COMPETITIVE LANDSCAPE

### 7.1 COMPANY PROFILES

7.1.1 Abbott Diabetes Care

7.1.2 Roche Diabetes Care

7.1.3 LifeScan

7.1.4 Dexcom Inc.

7.1.5 Medtronic PLC

7.1.6 Arkray Inc.

7.1.7 Ascensia Diabetes Care

7.1.8 Agamatrix Inc.

7.1.9 Bionime Corporation

7.1.10 Acon Laboratories Inc.

7.1.11 Trivida Health

### 7.2 COMPANY SHARE ANALYSIS

#### 7.2.1 Self-monitoring Blood Glucose Devices

7.2.1.1 Abbott Diabetes Care

7.2.1.2 Roche Diabetes Care

7.2.1.3 LifeScan

7.2.1.4 Others

#### 7.2.2 Continuous Glucose Monitoring Devices

7.2.2.1 Medtronic PLC

7.2.2.2 Abbott Diabetes Care

7.2.2.3 Others

## 8 MARKET OPPORTUNITIES AND FUTURE TRENDS

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

**Brazil Blood Glucose Monitoring - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2018 - 2029**

Market Report | 2024-02-17 | 70 pages | Mordor Intelligence

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

Select license	License	Price
	Single User License	\$4750.00
	Team License (1-7 Users)	\$5250.00
	Site License	\$6500.00
	Corporate License	\$8750.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-03"/>
		Signature	

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

